Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the safety and efficacy of using 0.1% tacrolimus ointment for long-term treatment of atopic dermatitis. DESIGN: Open-label, noncomparative study with 6 to 12 months of follow-up. SETTINGS: Outpatient departments in 30 study centers in 11 European countries. PATIENTS: We enrolled 316 patients aged 18 years and older with moderate to severe atopic dermatitis, 200 for 6 months and 116 for 12 months; 77.5% of patients completed the study. INTERVENTION: Twice-daily application of 0.1% tacrolimus ointment on all affected skin. Visits were scheduled on day 1; after 1, 2, and 4 weeks of treatment; and monthly thereafter. MAIN OUTCOME MEASURES: Safety assessments included monitoring of adverse events, clinical laboratory values, and tacrolimus blood concentrations. Efficacy end points included a combined score (modified Eczema Area and Severity Index) and an investigator's global assessment. RESULTS: Local irritation, adverse events such as burning sensation (47% of patients), pruritus (24% of patients), and erythema (12% of patients) were common but tended to occur only when initiating treatment. Laboratory values showed no marked changes over time. Systemic absorption was minimal, with the maximum tacrolimus blood concentration being less than 1 ng/mL in 76% of patients. All efficacy end points showed improvement. The mean (SD) modified Eczema Area and Severity Index score was 23.7 (12.6) at day 1, 13.5 (11.3) at week 1, 6.1 (9.2) at month 6, and 6.1 (8.1) at month 12. Marked or excellent improvement or clearance of disease was reported in 54%, 81%, and 86% of patients at week 1, month 6, and month 12, respectively. CONCLUSION: Up to 1 year of tacrolimus ointment use was safe and effective in patients with atopic dermatitis. Arch Dermatol. 2000;136:999-1006
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis
Ruzicka, T., Bieber, T., Schöpf, E., Rubins, A., Dobozy, A., Bos, J. D., Jablonska, S., Ahmed, I., Thestrup-Pedersen, K., Daniel, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371203 · Cited by 518
Self-citationGrading of the severity of atopic dermatitis.
Rajka, G., & Langeland, T. (1989) · PubMed · doi:10.2340/000155551441314 · Cited by 412
Boguniewicz, M., Fiedler, V. C., Raimer, S., Lawrence, I. D., Leung, D. Y. M., & Hanifin, J. M. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70281-7 · Cited by 309
(2006) · Springer eBooks · doi:10.1007/3-540-29856-8 · Cited by 273
Tacrolimus Ointment does not Affect Collagen Synthesis: Results of a Single-Center Randomized Trial
Reitamo, S., Rissanen, J., Remitz, A., Granlund, H., Erkko, P., Autio, P., Lauerma, A. I., & Elg, P. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00323.x · Cited by 273
Self-citationTacrolimus ointment for atopic dermatitis
NAKAGAWA, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92855-x · Cited by 233
Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis
Van Leent, E. J. M., Gräber, M., Thurston, M., Wagenaar, A., Spuls, P. I., & Bos, J. D. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.7.805 · Cited by 223
Kapp, A. (1993) · Allergy · doi:10.1111/j.1398-9995.1993.tb02167.x · Cited by 179
Disease Management of Atopic Dermatitis: a Practice Parameter
Leung, D. Y. M., Hanifin, J. M., Charlesworth, E. N., Li, J. T., Bernstein, I. L., Berger, W. E., Blessing-Moore, J., Fìneman, S. M., Lee, R. E., Nicklas, R. A., et al. (1997) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)63003-7 · Cited by 117
Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis
TOFTE, S. (1998) · Journal of the European Academy of Dermatology and Venereology · doi:10.1016/s0926-9959(98)95291-6 · Cited by 94
Recurrent viral infections in patients with past or present atopic dermatitis
Rystedt, I., Strannegård, I., & Strannegård, Ö. (1986) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1986.tb04064.x · Cited by 86
Significance of Elevated Serum LDH (Lactate Dehydrogenase) Activity in Atopic Dermatitis
Mukai, H., Noguchi, T., Kamimura, K., Nishioka, K., & Nishiyama, S. (1990) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1990.tb01679.x · Cited by 74
Changes in Cell-Mediated Immunity in Atopic Eczema
Strannegård, Ö., & Strannegård, I. (1991) · Springer eBooks · doi:10.1007/978-3-662-02671-7_24 · Cited by 12
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationGuidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationAtopic dermatitis: A practice parameter update 2012
Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Metadata
- Authors
- Reitamo, S.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2000-08-01
- Volume
- 136
- Issue
- 8
- Pages
- 999
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2141900212
- Cited by
- 378
- References
- 14
- FWCI
- 36.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.